Xyloglucan Core-Shell Tablet for Reliable Colon Drug Release
Solution Overview
Problem
Current delivery modalities for oral administration fail to achieve reliable and efficient targeted release of active pharmaceutical ingredients (APIs) to the colon, leading to variable therapeutic outcomes due to intra- and inter-individual pH variability in the gut, premature release in the small intestine, and systemic absorption, which compromises therapeutic index and local efficacy.
Innovation Solution
A core-shell tablet formulation using native, highly purified cold-water soluble xyloglucan as a matrix and a pH-responsive coating, where the xyloglucan matrix forms a viscous gel in the small intestine and is digested by colonic microbiota for targeted release in the colon, combined with an enteric coating to stabilize the tablet during gastric passage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a pH-responsive coating is used to target colon release, then colonic delivery is improved, but premature release in the small intestine occurs due to pH variability
Solution Approach 1:
The coating is segmented into multiple functional layers: an inner pH-responsive layer for colon targeting and an outer protective layer that shields the inner layer from premature pH-triggered dissolution in the small intestine. This segmentation allows each layer to perform its specific function independently, improving reliability while preventing premature release.
Solution Approach 2:
The outer protective coating acts as an intermediary barrier between the inner pH-responsive coating and the small intestine environment. This intermediary layer prevents direct interaction between the pH-responsive coating and variable pH conditions in the small intestine, thereby preventing premature release while preserving the colon-targeting capability.
2Stability of the object's composition
If native xyloglucan is used as a matrix, then viscosity and gel formation are improved, but manufacturing precision is reduced due to solubility variability
Solution Approach 1:
The native xyloglucan is chemically modified by controlling the degree of substitution and molecular weight to optimize its cold-water solubility. This parameter change ensures consistent gel formation and viscosity across batches while maintaining the desired stability of composition, thereby resolving the conflict between gel stability and manufacturing precision.
3Reliability
If a multi-layer coating is applied, then protection against premature release is improved, but device complexity increases
Solution Approach 1:
Different regions of the coating structure are assigned different qualities and functions: the inner layer provides pH-responsive release control while the outer layer provides mechanical protection and pH buffering. This local differentiation of qualities allows the system to achieve reliable protected release without requiring excessive complexity, as each layer is optimized for its specific local function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ensures minimal API release in the small intestine, maximizing colonic delivery with zero-order kinetics, enhancing therapeutic efficacy for conditions like inflammatory bowel disease and colon cancer, while minimizing systemic side effects.
Implementation Method 1
the xyloglucan matrix forms a viscous gel in the small intestine
Implementation Method 2
forms a viscous gel
Implementation Method 3
a pH-responsive coating, where the xyloglucan matrix forms a viscous gel in the small intestine and is digested by colonic microbiota for targeted release in the colon
Implementation Method 4
digested by colonic microbiota for targeted release in the colon
Implementation Method 5
digested by colonic microbiota
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Pharmaceutical formulation dosage form (1) with a core (2) encapsulated by at least one shell (3) and comprising at least one active pharmaceutical ingredient (4), wherein the at least one active pharmaceutical ingredient (4) is embedded in said core (2) of the pharmaceutical formulation dosage form (1), preferably in that said core (2) is formed by a matrix based on xyloglucan (5) containing said active pharmaceutical ingredient (4), and wherein said shell (3) is a pH-responsive coating.
